Fulgent Genetics (NASDAQ:FLGT) Insider Sells $32,891.18 in Stock

Fulgent Genetics, Inc. (NASDAQ:FLGT – Get Free Report) insider Hanlin Gao sold 1,673 shares of the company’s stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $19.66, for a total transaction of $32,891.18. Following the transaction, the insider owned 986,117 shares of the company’s stock, valued at approximately $19,387,060.22. This represents a 0.17% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

• Can Fulgent Sustain Sky-High Growth Post-Pandemic?

Hanlin Gao also recently made the following trade(s):

• On Thursday, August 27th, Hanlin Gao sold 939 shares of Fulgent Genetics stock. The stock was sold at an average price of $19.91, for a total value of $18,695.49.

Fulgent Genetics Price Performance

Shares of NASDAQ FLGT traded down $0.39 during mid-day trading on Thursday, hitting $19.65. 283,530 shares of the company’s stock traded hands, compared to its average volume of 233,486. Fulgent Genetics, Inc. has a 1 year low of $13.46 and a 1 year high of $31.04. The company’s 50-day moving average is $19.71 and its two-hundred day moving average is $18.01. The company has a market capitalization of $540.57 million, a P/E ratio of -6.97 and a beta of 0.93.

Fulgent Genetics (NASDAQ:FLGT – Get Free Report) last issued its quarterly earnings data on Thursday, July 30th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.12). The company had revenue of $85.39 million for the quarter, compared to analysts’ expectations of $94.00 million. Fulgent Genetics had a negative net margin of 26.05% and a negative return on equity of 4.93%. Fulgent Genetics has set its FY 2026 guidance at -2.350–2.220 EPS. Equities analysts anticipate that Fulgent Genetics, Inc. will post -3.48 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. Piper Sandler lifted their price objective on shares of Fulgent Genetics from $15.00 to $19.00 and gave the stock a “neutral” rating in a research note on Tuesday, August 4th. Wall Street Zen upgraded shares of Fulgent Genetics from a “strong sell” rating to a “sell” rating in a report on Saturday, August 29th. Finally, Weiss Ratings raised shares of Fulgent Genetics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 27th. One equities research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $27.50.

View Our Latest Report on FLGT

Hedge Funds Weigh In On Fulgent Genetics

A number of large investors have recently bought and sold shares of FLGT. Moore Capital Management LP grew its position in Fulgent Genetics by 4.8% in the 2nd quarter. Moore Capital Management LP now owns 48,343 shares of the company’s stock valued at $992,000 after acquiring an additional 2,219 shares during the last quarter. Empowered Funds LLC purchased a new stake in shares of Fulgent Genetics during the second quarter valued at $276,000. Public Employees Retirement System of Ohio purchased a new stake in shares of Fulgent Genetics during the second quarter valued at $1,134,000. Almitas Capital LLC bought a new position in shares of Fulgent Genetics in the second quarter worth about $2,150,000. Finally, Corient Private Wealth LP purchased a new position in Fulgent Genetics in the 2nd quarter worth about $880,000. Hedge funds and other institutional investors own 48.06% of the company’s stock.

Fulgent Genetics Company Profile

(Get Free Report)

Fulgent Genetics, Inc NASDAQ: FLGT is a California-based company specializing in high-complexity genetic testing and diagnostic services. Operating from its headquarters in Temple City, Fulgent leverages next-generation sequencing (NGS) technologies and advanced bioinformatics to deliver a broad range of clinical and research assays. The company’s infrastructure includes CAP- and CLIA-certified laboratories, enabling it to process large volumes of samples with rapid turnaround times.

Fulgent’s product portfolio encompasses hereditary cancer panels, rare disease and neuromuscular disorder testing, pharmacogenomic screenings, non-invasive prenatal tests, and infectious disease assays including COVID-19 diagnostics.

Featured Articles

• Five stocks we like better than Fulgent Genetics
• The Path to $230 Billion: Broadcom Outlines the Next Phase of Its AI Growth Story
• NVIDIA’s Hugging Face Deal Raises a Bigger Question About Its AI Moat Now
• Dropping the Dough: Yum! Brands Strategically Trims the Fat
• These 3 Stock Charts Just Flashed the Dreaded Death Cross Pattern

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Fulgent Genetics Right Now?

Before you consider Fulgent Genetics, you’ll want to hear this.

MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Fulgent Genetics wasn’t on the list.

While Fulgent Genetics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here